We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

SARS-CoV-2 RT-PCR Test Uses Three-in-One Media Pooling Strategy to Increase Testing Throughput

By LabMedica International staff writers
Posted on 02 May 2022
Print article
Image: ViroKey SARS-CoV-2 RT-PCR Test v2.0 can now be used for pooling (Photo courtesy of Pexels)
Image: ViroKey SARS-CoV-2 RT-PCR Test v2.0 can now be used for pooling (Photo courtesy of Pexels)

A SARS-CoV-2 RT-PCR test uses a three-in-one media pooling strategy in order to provide the additional capability to be used for pooling.

The ViroKey SARS-CoV-2 RT-PCR Test v2.0, developed by Vela Diagnostics (Singapore) for the detection of SARS-CoV-2, received its EUA in September 2020, has CE mark in the EU, and is also approved by Australian TGA and multiple regulatory authorities globally. The FDA EUA authorized indication for the test for the detection of SARS-CoV-2 makes it authorized for use in laboratories certified under CLIA to perform high complexity tests, for the qualitative detection of RNA from the SARS-CoV-2 in pooled samples containing aliquots of transport media from up to three individual human anterior nasal swab specimens from not only individuals who are symptomatic, but also those who are asymptomatic and are participation in serial testing programs.

With at least three workflows available, laboratories can leverage that flexibility, depending on the throughput of their laboratory. This pooling strategy can be done by combining sample media of up to three patients to be tested as one sample, thereby only using resources needed for a single test. In a population with low positivity rate, this method increases testing throughput, improves laboratory efficiency, and reduces overall cost of testing.

"At Vela Diagnostics, we aim to provide solutions that work in real situations. With the FDA encouraging the development of tests for pooled samples, we have added the ability to aid in the increase of testing throughput," said Sam Dajani, Chairman and CEO of Vela Diagnostics.

"Laboratories can now leverage this capability to cope with the sudden surges that we have all experienced in waves throughout this pandemic," said Scott Cassidy, Director of Business Development. "We believe this is an important capability in the COVID-19 pandemic, where incidences and levels of testing can fluctuate at any time."

Related Links:
Vela Diagnostics 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
COVID-19 Rapid Test
AQ+ COVID-19 Ag Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more